6. Parkinson disease Clinical trials / Disease details

Clinical trials : 2,307 / Drugs : 2,007 - (DrugBank : 349) / Drug target genes : 188 - Drug target pathways : 199

7 trials found

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05094011 (ClinicalTrials.gov)	March 1, 2023	20/7/2021	Evaluating Safety, Tolerability, and Efficacy of Autologous MitoCell Transplantation in Subjects With Idiopathic Parkinson's Disease	A Phase I Open-Label Dose-Escalation Study to Evaluate the Safety, Tolerability, and Efficacy of Autologous MitoCell (Adipose-Derived Mesenchymal Stem Cells) Transplantation in Subjects With Idiopathic Parkinson's Disease	Idiopathic Parkinson's Disease	Biological: Aadipose-Derived Mesenchymal Stem Cells	Taiwan Mitochondrion Applied Technology Co., Ltd.	NULL	Not yet recruiting	45 Years	70 Years	All	9	Phase 1	NULL
2	NCT05152394 (ClinicalTrials.gov)	January 2022	29/11/2021	Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cells for Parkinson's Disease	Safety of Cultured Allogeneic Adult Umbilical Cord Derived Mesenchymal Stem Cell Intravenous Infusion for the Treatment of Parkinson's Disease	Parkinson Disease	Biological: AlloRx	The Foundation for Orthopaedics and Regenerative Medicine	NULL	Not yet recruiting	N/A	N/A	All	20	Phase 1	Antigua and Barbuda
3	NCT04506073 (ClinicalTrials.gov)	November 9, 2020	16/7/2020	Phase IIa Randomized Placebo Controlled Trial: Mesenchymal Stem Cells as a Disease-modifying Therapy for iPD	Allogeneic Bone Marrow-derived Mesenchymal Stem Cells as a Disease-modifying Therapy for Idiopathic Parkinson's Disease: Phase IIa Double-blind Randomized Placebo Controlled Trial	Parkinson's Disease	Drug: MSC+placebo;Drug: MSC;Drug: Placebo	The University of Texas Health Science Center, Houston	Michael J. Fox Foundation for Parkinson's Research	Active, not recruiting	50 Years	79 Years	All	45	Phase 2	United States
4	NCT03684122 (ClinicalTrials.gov)	June 1, 2018	23/9/2018	Use of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) in People With Parkinson's (PD).	A Safety and Efficacy Study of the Effects of Mesenchymal Stem Cells (MSCs) Differentiated Into Neural Stem Cells (NSCs) on the Motor and Non-motor Symptoms in People With Parkinson's Disease (PD).	Parkinson Disease	Biological: Injection of Umbilical cord derived MSCs	University of Jordan	NULL	Active, not recruiting	20 Years	75 Years	All	10	Phase 1/Phase 2	Jordan
5	NCT03550183 (ClinicalTrials.gov)	January 10, 2018	11/5/2018	Umbilical Cord Derived Mesenchymal Stem Cells Therapy in Parkinson's Disease	Safety and Efficacy Investigation of Patients With Parkinson's Disease by Transplantation of Umbilical Cord Derived Mesenchymal Stem Cells	Parkinson's Disease	Biological: mesenchymal stem cells	Hebei Newtherapy BIo-Pharma technology Co., Ltd.	NULL	Enrolling by invitation	40 Years	80 Years	All	20	Phase 1	China
6	NCT04146519 (ClinicalTrials.gov)	July 1, 2017	18/10/2019	Parkinson's Disease Therapy Using Cell Technology	Developent and Implement a Method of Parkinson's Disease Therapy Using Cell Technology	Transplantation:Mesenchymal Stem Cell Transplantation	Biological: Autologous mesenchymal stem cells;Other: Placebo	Belarusian Medical Academy of Post-Graduate Education	NULL	Recruiting	18 Years	69 Years	All	50	Phase 2/Phase 3	Belarus
7	NCT01446614 (ClinicalTrials.gov)	October 2011	4/10/2011	Mesenchymal Stem Cells Transplantation to Patients With Parkinson's Disease	Phase?/?Trial of Autologous Bone Marrow Derived Mesenchymal Stem Cells to Patients With Parkinson's Disease.	Parkinson's Disease	Biological: bone marrow derived mesenchymal stem cells	Guangzhou General Hospital of Guangzhou Military Command	NULL	Recruiting	30 Years	65 Years	Both	20	Phase 1/Phase 2	China